Lack of association between TNF-308 polymorphism and the clinical and immunological characteristics of systemic lupus erythematosus and primary Sjögren's syndrome

Objective: To investigate the previously reported association of tumor necrosis factor alpha (TNF) -308 single nucleotide polymorphism (SNP) with the clinical course and immunological features in patients with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS). Methods: The...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2005
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/23669
Acceso en línea:
https://repository.urosario.edu.co/handle/10336/23669
Palabra clave:
Autoantibody
Tumor necrosis factor
Adult
Allele
Article
Blood sampling
Clinical feature
Clinical protocol
Controlled study
Disease activity
Disease course
Environmental factor
Enzyme linked immunosorbent assay
Female
Genetic analysis
Human
Immune response
Immunology
Major clinical study
Male
Polymerase chain reaction
Priority journal
Protein analysis
Protein blood level
Restriction fragment length polymorphism
Single nucleotide polymorphism
Sjoegren syndrome
Systemic lupus erythematosus
Adult
Enzyme-linked immunosorbent assay
Female
Genetic predisposition to disease
Health status
Humans
Male
Severity of illness index
Sjogren's syndrome
Tumor necrosis factor-alpha
Polymorphism
Primary sjögren's syndrome
Systemic lupus erythematosus
Tumor necrosis factor
systemic
single nucleotide
Lupus erythematosus
Polymorphism
Rights
License
Abierto (Texto Completo)
Description
Summary:Objective: To investigate the previously reported association of tumor necrosis factor alpha (TNF) -308 single nucleotide polymorphism (SNP) with the clinical course and immunological features in patients with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS). Methods: The studied group consisted of 113 consecutive SLE and 65 pSS patients. TNF -308 SNP was determined by the polymerase chain reaction-restriction fragment length polymorphism technique. Clinical and immunological characteristics were assessed according to a standard protocol that included disease activity (SLEDAI) and damage (SLICC Damage Index). Serum TNF? levels were measured in samples collected from 32 patients with SLE and 16 with pSS by enzyme-linked immunosorbent assay. Results: The TNF2 allele (A) was observed in 46% and 54% of SLE and pSS patients, respectively. We failed to find any significant association between the -308 SNP and disease manifestations, the presence of autoantibodies or cytokine levels in either group. Conclusion: TNF -308 SNP (TNF2) does not exhibit a significant influence on the disease course or immunological response in SLE and pSS. Other genetic and/or environmental factors seem to be required and to be more important than TNF2 allele for the progression of these diseases.